Detection of AD Biomarkers in Tear Fluid

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04620902

Acronym

SmartTears

Enrollment

Registered

2020-11-09

Start date

2018-01-01

Completion date

2020-01-01

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Impairment

Brief summary

Detection of AD biomarkers in tear fluid

Interventions

OTHERTear sampling

Tear sampling using Schirmer's strips

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* . Inclusion criteria were an MMSE score ≥ 20 and a CDR score from 0 to 1, thereby including patients across the whole clinical spectrum (i.e. from subjective cognitive disorder to (mild) dementia).

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Level of AD biomarkers in tear fluid	Baseline

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026